KPMG - Solvency II paper, "Beyond compliance towards optimisation"

Another titbit from the Big 4, this time covering the benefits that are available off the back off the legislative delays, specifically around optimising the Finance and Risk functions. If you are one of the Tier 1 companies, this comes across as a bit of a "Where's Wally" paper (or 'Waldo' for my American pals!), as it borrows of their extensive 'experience' on site with clients over the last few years. Despite that extensive experience, this is pretty light at a fistful of pages.

I would struggle to distinguish between 'capital minimisation' and 'capital optimisation', which they start off with, but they go on to describe a world of risk and finance "centres of excellence, which utilise the good work currently being done on the data warehousing front by Data teams to populate the various regulatory reporting requirements as well as management information needs, and that all sounds plausible.

The Risk section is naturally a little flannel-y, but suggests the best functions will be able to predict cash flows better, ultimately improving risk, capital and business planning and as a by-product, RAROC comprehension and enhancement.

Not a lot else, but some ideas around communicating future value of today's expenditure at the very least.

KPMG Paper - Solvency II still fit for purpose?

A handy survey from one of the Big 4 on some of the biggest challenges remaining on Solvency II. Small sample (20 people), and is GI-flavoured, but that doesn't make the experiences any less relevant to you 'Lifers' out there. The following was noteworthy;

• A good half of respondents expect their capital models to be a key driver in their business planning process post- Solvency II, with the remainder using it as a "reasonable consideration" - this contrasts with a quarter who use them to a negligible degree if at all pre-Solvency II.
• Suggestion that, with Solvency II accounting being viewed as a "regulatory exercise" for non-lifers, there is plenty of transitional work to do in order to align the GAAP/IFRS view with the Solvency II accounting view
• Concerns around reporting lines for different strands of actuarial activity (pricing, reserving and capital) potentially going into one executive, with those assessing risk versus those taking it being the primary issue.
• Suggestion that the increased requirements around actuarial staffing may drive some work offshore in order to reduce the costs
• Concerns around calculation of Risk Margin, specifically around what the Finance function will demand versus what the Actuarial function can provide.
• Comment that, as the internal model is expected to change as a business's risk profile changes, that current best practice ensures this is done at least annually, though monitoring of new business (therefore plan against portfolio) agaist forecast is done more frequently - no lead on size of divergence that might drive a model change however, which was one of Mr Adam's bugbears from the speech last week.
  
• The provision of Actuarial opinions regarding the adequacy of reinsurance and underwriting arrangements appears to have split the respondents, with a decent number taking a wait-and-see approach - KMPG are similarly guarded when providing their own view, highlighting concerns with the impact of opinions on decision making and how they are worded.
• Further areas of collaboration between Risk, Actuarial and Finance functions are expected around Capital Management, Performance Management and ORSA, with devolution of previously shared responsibilities made to first line functions, and the second line becoming a multi-skilled "centre of excellence" - nice schematic to go with this on page 18.

Finanzplatz Munchen Initiative - Solvency II and Basel III impacts for corporate Germany

Whilst I try to restrict my German exposure to Rammstein and beer (ideally both!), this particular piece of research from the Munich Financial Centre Initiative was too substantial to ignore, covering the likely impact of Solvency II (and Basel to a lesser extent) on corporate financing across Germany (summary here).

It loses a little subtlety in translation, but the research certainly helps draw attention to the lobbying direction of the German contingent in CEA, focusing on the detailed investment strategies of national insurers (favouring the routing of institutional investment via banks, being big in the world of hybrids etc). It draws particular attention to the intra-national differences between Germany versus the French and British on these matters. It also suggests that the threats of Solvency II and Basel III twinned have had a substantial downward pressure on insurer stock prices.

It ends by strongly suggesting the EU trigger a QIS to consider the reciprocal effects of the two pieces of legislation, and push those results to the relevant bodies (EIOPA in our case).

Ultimately, my read would be that of all the transitionals currently on the table, the classification and eligibility of own funds would be highest on their list, and if they could squeeze in any calibration-related changes on long-dated debt all the better